Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Ono Pharma and Boehringer Ingelheim both added to their cancer ... The Japanese drugmaker's clinical-stage pipeline does not currently feature any ADCs, which have transformed the treatment ...

Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition ...

Boehringer Ingelheim and Circle Pharma have entered ... The latest deal will strengthen the oncology pipeline of Boehringer, which includes a range of cancer cell-directed and immuno-oncology ...

This partnership is a significant step toward Boehringer Ingelheim’s goal of transforming cancer care. It bolsters the already robust oncology pipeline of cancer cell-directed and immuno ...

At its Second International Research & Development Press Conference, Boehringer Ingelheim unveiled a pipeline of unique oral anti-diabetic compounds in phase II and III, establishing the Company ...

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.

Promising pipeline schizophrenia such as Ulotaront ... 2021. In March 2024, Boehringer Ingelheim and Sosei Group Corporation announced that they had entered a global collaboration and exclusive ...

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...